PMID: 22552454May 4, 2012Paper

Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China

The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases
Jun ChenShunqing Xu

Abstract

The study aimed to investigate gyrA and gyrB mutations in Mycobacterium tuberculosis (MTB) clinical strains from 93 patients with pulmonary tuberculosis in Hubei Province, China, and analyze the association between mutation patterns of the genes and ofloxacin resistance level. Among 93 MTB clinical isolates, 61 were ofloxacin-resistant by the proportion method, and 32 were ofloxacin-susceptible MDR-TB. No mutation in the gyrB gene was found in any MTB strains. In the 61 ofloxacin-resistant isolates, 54 mutations were observed in the gyrA gene. Only one mutation in the gyrA gene was found in ofloxacin-susceptible MDR-TB isolates. In this study, the mutation patterns of gyrA involved seven patterns of single codon mutation (A90V, S91P, S91T, D94N, D94Y, D94G or D94A) and two patterns of double codons mutation (S91P & D94H, S91P & D94A). The ofloxacin minimal inhibitory concentrations (MICs) of three patterns of single codon mutations in the gyrA gene (codons 94, 90 and 91) showed a statistically significant difference (p < 0.0001). The gyrA mutations at codons 90, 91 and 94 constitute the primary mechanism of fluoroquinolone resistance in MTB, and mutations at codon 91 in the gyrA gene may be associated with low-level resistance ...Continue Reading

References

Oct 15, 1994·FEMS Microbiology Letters·V Jarlier, H Nikaido
Oct 8, 1999·The Journal of Antimicrobial Chemotherapy·S H Gillespie, O Billington
Nov 5, 2003·Diagnostic Microbiology and Infectious Disease·Soo-Young KimChang-Suk Kang
Oct 6, 2005·The Journal of Antimicrobial Chemotherapy·Tsi-Shu HuangYung-Ching Liu
Dec 12, 2007·Antimicrobial Agents and Chemotherapy·Charles A PeloquinJohn L Johnson
Jun 19, 2008·Antimicrobial Agents and Chemotherapy·Igor MokrousovNalin Rastogi
Aug 19, 2009·Antimicrobial Agents and Chemotherapy·Andrea Von GrollPedro Almeida da Silva
Sep 2, 2010·Antimicrobial Agents and Chemotherapy·Julien PoissyNicolas Veziris

❮ Previous
Next ❯

Citations

Apr 19, 2013·Journal of Molecular Recognition : JMR·Raja Mohmed Beema ShafreenShunmugiah Karutha Pandian
Dec 24, 2014·Antimicrobial Agents and Chemotherapy·Christine BernardAlexandra Aubry
Apr 30, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Fernanda MaruriTimothy R Sterling
Oct 31, 2020·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Sajid AliMuhammad Irfan
Jun 24, 2021·International Journal of Antimicrobial Agents·Pratchakan ChaiyachatKiatichai Faksri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.